TY - JOUR
T1 - Breast-cancer-specific mortality in patients treated based on the 21-gene assay
T2 - A SEER population-based study
AU - Petkov, Valentina I.
AU - Miller, Dave P.
AU - Howlader, Nadia
AU - Gliner, Nathan
AU - Howe, Will
AU - Schussler, Nicola
AU - Cronin, Kathleen
AU - Baehner, Frederick L.
AU - Cress, Rosemary
AU - Deapen, Dennis
AU - Glaser, Sally L.
AU - Hernandez, Brenda Y.
AU - Lynch, Charles F.
AU - Mueller, Lloyd
AU - Schwartz, Ann G.
AU - Schwartz, Stephen M.
AU - Stroup, Antoinette
AU - Sweeney, Carol
AU - Tucker, Thomas C.
AU - Ward, Kevin C.
AU - Wiggins, Charles
AU - Wu, Xiao Cheng
AU - Penberthy, Lynne
AU - Shak, Steven
N1 - Publisher Copyright:
© 2016 Breast Cancer Research Foundation/Macmillan Publishers Limited.
PY - 2016/12/14
Y1 - 2016/12/14
N2 - The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40–84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (N = 38,568). Unadjusted 5-year BCSM were 0.4% (n = 21,023; 95% confidence interval (CI), 0.3–0.6%), 1.4% (n = 14,494; 95% CI, 1.1–1.7%), and 4.4% (n = 3,051; 95% CI, 3.4–5.6%) for Recurrence Score <18, 18–30, and ≥ 31 groups, respectively (P<0.001). In multivariable analysis adjusted for age, tumor size, grade, and race, the Recurrence Score result predicted BCSM (P<0.001). Among patients with node-positive disease (micrometastases and up to three positive nodes; N = 4,691), 5-year BCSM (unadjusted) was 1.0% (n = 2,694; 95% CI, 0.5–2.0%), 2.3% (n = 1,669; 95% CI, 1.3–4.1%), and 14.3% (n = 328; 95% CI, 8.4– 23.8%) for Recurrence Score <18, 18–30, ≥ 31 groups, respectively (P<0.001). Five-year BCSM by Recurrence Score group are reported for important patient subgroups, including age, race, tumor size, grade, and socioeconomic status. This SEER study represents the largest report of prospective BCSM outcomes based on Recurrence Score results for patients with HR+, HER2-negative, node-negative, or node-positive breast cancer, including subgroups often under-represented in clinical trials.
AB - The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recurrence Score results and clinical covariates, the National Cancer Institute collaborated with Genomic Health and 14 population-based registries in the the Surveillance, Epidemiology, and End Results (SEER) Program to electronically supplement cancer surveillance data with Recurrence Score results. The prespecified primary analysis cohort was 40–84 years of age, and had node-negative, HR+, HER2-negative, nonmetastatic disease diagnosed between January 2004 and December 2011 in the entire SEER population, and Recurrence Score results (N = 38,568). Unadjusted 5-year BCSM were 0.4% (n = 21,023; 95% confidence interval (CI), 0.3–0.6%), 1.4% (n = 14,494; 95% CI, 1.1–1.7%), and 4.4% (n = 3,051; 95% CI, 3.4–5.6%) for Recurrence Score <18, 18–30, and ≥ 31 groups, respectively (P<0.001). In multivariable analysis adjusted for age, tumor size, grade, and race, the Recurrence Score result predicted BCSM (P<0.001). Among patients with node-positive disease (micrometastases and up to three positive nodes; N = 4,691), 5-year BCSM (unadjusted) was 1.0% (n = 2,694; 95% CI, 0.5–2.0%), 2.3% (n = 1,669; 95% CI, 1.3–4.1%), and 14.3% (n = 328; 95% CI, 8.4– 23.8%) for Recurrence Score <18, 18–30, ≥ 31 groups, respectively (P<0.001). Five-year BCSM by Recurrence Score group are reported for important patient subgroups, including age, race, tumor size, grade, and socioeconomic status. This SEER study represents the largest report of prospective BCSM outcomes based on Recurrence Score results for patients with HR+, HER2-negative, node-negative, or node-positive breast cancer, including subgroups often under-represented in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85014016510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014016510&partnerID=8YFLogxK
U2 - 10.1038/npjbcancer.2016.17
DO - 10.1038/npjbcancer.2016.17
M3 - Article
AN - SCOPUS:85014016510
VL - 2
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 16017
ER -